SARS-CoV2 anti-spike IgG response following COVID-19 mRNA vaccination (BNT162b2) in patients with hematological disorders
This is a prospective study conducted to determine the level of anti-spike IgG to SARS-CoV-2 2-6 weeks following the BNT162b2 vaccination in 125 patients with hematological disorders. Compared with healthy controls, patients with malignant lymphoma had lower rates of seropositivity and lower levels of antibody titer. Furthermore, patients who received rituximab (R)-containing chemotherapy had lower antibody titers than those who were not treated with R or who had completed R-containing chemotherapy more than 9 months earlier. Despite having 71% IgG-seropositivity, patients with multiple myeloma had lower antibody titers than the control group. Furthermore, patients receiving daratumumab-containing chemotherapy had lower antibody titers than those not receiving treatment. Moreover, patients with acute myeloid leukemia or myelodysplastic syndrome had lower antibody titers than the control group. Overall, the number of peripheral blood lymphocytes was significantly correlated with IgG titers, with seropositive patients having more peripheral blood lymphocytes than seronegative patients. Patients with severe immunosuppression, such as those with hematological disorders, often have impaired seroconversion with COVID-19 vaccination that should be taken into consideration by clinicians.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:63 |
|---|---|
| Enthalten in: |
Rinsho ketsueki] The Japanese journal of clinical hematology - 63(2022), 4 vom: 25., Seite 247-253 |
| Sprache: |
Japanisch |
|---|
| Beteiligte Personen: |
Hagihara, Masao [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Viral |
|---|
| Anmerkungen: |
Date Completed 03.05.2022 Date Revised 03.05.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.11406/rinketsu.63.247 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34019989X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34019989X | ||
| 003 | DE-627 | ||
| 005 | 20231226004614.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||jpn c | ||
| 024 | 7 | |a 10.11406/rinketsu.63.247 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1133.xml |
| 035 | |a (DE-627)NLM34019989X | ||
| 035 | |a (NLM)35491212 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a jpn | ||
| 100 | 1 | |a Hagihara, Masao |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SARS-CoV2 anti-spike IgG response following COVID-19 mRNA vaccination (BNT162b2) in patients with hematological disorders |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.05.2022 | ||
| 500 | |a Date Revised 03.05.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a This is a prospective study conducted to determine the level of anti-spike IgG to SARS-CoV-2 2-6 weeks following the BNT162b2 vaccination in 125 patients with hematological disorders. Compared with healthy controls, patients with malignant lymphoma had lower rates of seropositivity and lower levels of antibody titer. Furthermore, patients who received rituximab (R)-containing chemotherapy had lower antibody titers than those who were not treated with R or who had completed R-containing chemotherapy more than 9 months earlier. Despite having 71% IgG-seropositivity, patients with multiple myeloma had lower antibody titers than the control group. Furthermore, patients receiving daratumumab-containing chemotherapy had lower antibody titers than those not receiving treatment. Moreover, patients with acute myeloid leukemia or myelodysplastic syndrome had lower antibody titers than the control group. Overall, the number of peripheral blood lymphocytes was significantly correlated with IgG titers, with seropositive patients having more peripheral blood lymphocytes than seronegative patients. Patients with severe immunosuppression, such as those with hematological disorders, often have impaired seroconversion with COVID-19 vaccination that should be taken into consideration by clinicians | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a BNT162b2 | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Hematological disorders | |
| 650 | 4 | |a IgG antibody | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 650 | 7 | |a RNA, Viral |2 NLM | |
| 650 | 7 | |a BNT162 Vaccine |2 NLM | |
| 650 | 7 | |a N38TVC63NU |2 NLM | |
| 700 | 1 | |a Sugi, Tomiyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Uchida, Tomoyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Ohara, Shin |e verfasserin |4 aut | |
| 700 | 1 | |a Imai, Yui |e verfasserin |4 aut | |
| 700 | 1 | |a Inoue, Morihiro |e verfasserin |4 aut | |
| 700 | 1 | |a Mitamura, Keiko |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Rinsho ketsueki] The Japanese journal of clinical hematology |d 1972 |g 63(2022), 4 vom: 25., Seite 247-253 |w (DE-627)NLM000222178 |x 0485-1439 |7 nnns |
| 773 | 1 | 8 | |g volume:63 |g year:2022 |g number:4 |g day:25 |g pages:247-253 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.11406/rinketsu.63.247 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 63 |j 2022 |e 4 |b 25 |h 247-253 | ||